- Relay Medical (RELA) & Fio commence COVID-19 rapid testing for U.S. departing passengers at Toronto Pearson Airport
- U.S. passengers can book their rapid test between 72 hours and 2.5 hours in advance of their flight departure
- Fionet digital workflow, testing, and data infrastructure is deployed at Toronto Pearson to help manage COVID-19 testing
- Relay Medical is a technology innovator headquartered in Toronto, Canada
- Relay Medical Corp. (RELA) is up 3.51 per cent and is trading at C$0.59 at 12:50 pm ET
The Fionet Platform has been successfully deployed at Toronto Pearson International Airport and currently managing COVID-19 rapid testing for US-bound passengers.
Using the Fionet Platform, departing U.S. passengers can book their rapid test between 72 hours and 2.5 hours in advance of their flight departure time using their personal mobile device at gtaa.fionarapidresponse.com.
Once arrived at Toronto Pearson, passengers check-in for their appointment, get tested, and wait for their results notification via text or email and view their results through the Fionet Platform.
Toronto Pearson is Canada's largest and busiest airport, serving more than 50 million passengers in 2019, and one of only four airports accepting international flights into Canada.
The Centers for Disease Control and Prevention (CDC) within the Department of Health and Human Services (HHS) issued an Order on January 12, 2021, requiring proof of a negative COVID-19 test or documentation of having recovered from COVID-19 for all air passengers arriving from a foreign country to the US.
Negative results from the Toronto Pearson testing program, including Antigen COVID-19 tests, can be relied on for travel to the U.S.
Under the terms of the engagement with Toronto Pearson, the Fionet digital workflow, testing, and data infrastructure is deployed at Toronto Pearson to help manage COVID-19 testing for both passengers and employees.
The testing program utilizes Fionet's high-throughput testing solution, including multiple mobile point-of-need devices connected in real-time to cloud data services, processing high quantities of rapid antigen tests per hour and capable of turning around test results within 20 minutes.
The Fionet Platform will also manage passenger scheduling, rapid test processing, real-time results reporting, integration with LuminUltra PCR devices, Response Biomedical antigen rapid diagnostic tests (RDTs) and devices, Abbott Panbio antigen RDTs, and all corresponding data and messaging flows.
The Fionet Platform will enable easy passenger scheduling and registration from mobile phones followed by coordinated mass testing, while continuously capturing and securely transmitting test results, with full privacy protection.
Relay Medical is a technology innovator headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics, AI data science and cybersecurity sectors.
Relay Medical Corp. (RELA) is up 3.51 per cent and is trading at C$0.59 at 12:50 pm ET.